Abstract |
The therapeutic efficacy of antineoplastic purine analogs can be jeopardized by the emergence of drug-resistant mutant subpopulations of tumor cells. To determine whether such mutant populations might be eradicable in vivo with the type of HAT combination ( hypoxanthine + an antifolate + thymidine) known to be selectively cytotoxic to them in vitro, 2 thioguanine-resistant BALB/c murine myeloma lines were transplanted into BALB/c mice to produce tumors capable of progressive growth in the absence of therapy. Treatment of these mice with a modified HAT regimen induced permanent tumor regressions in 37/44 mice; the same treatment was ineffective against tumors produced by a non-mutant myeloma line from which one of the mutant sublines had been derived.
|
Authors | F L Moolten |
Journal | Cancer letters
(Cancer Lett)
Vol. 31
Issue 3
Pg. 305-9
(Jun 1986)
ISSN: 0304-3835 [Print] Ireland |
PMID | 3719570
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Hypoxanthines
- Hypoxanthine
- Thioguanine
- Aminopterin
- Thymidine
|
Topics |
- Aminopterin
(administration & dosage, therapeutic use)
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Drug Resistance
- Hypoxanthine
- Hypoxanthines
(administration & dosage, therapeutic use)
- Mice
- Mice, Inbred BALB C
- Mutation
- Plasmacytoma
(drug therapy)
- Thioguanine
(therapeutic use)
- Thymidine
(administration & dosage, therapeutic use)
|